Oral Tongue Cancer in a Patient with Fanconi Anemia: A Case Report and Literature Review

References

• Bhandari J, Thada PK, Puckett Y. Fanconi anemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2020.
   Google Scholar
• Furlong E, Carter T. Aplastic anaemia: current concepts in diagnosis and management. J Paediatr Child Health. 2020;56(7):1023–1028.32619069
   PubMed Web of Science ®Google Scholar
• Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101(4):1249–1256.12393516
   PubMed Web of Science ®Google Scholar
• Solomon PJ, Margaret P, Rajendran R, et al. A case report and literature review of Fanconi Anemia (FA) diagnosed by genetic testing. Ital J Pediatr. 2015;41:38.25953249
   PubMed Web of Science ®Google Scholar
• Meetei AR, Levitus M, Xue Y, et al. X-linked inheritance of Fanconi anemia complementation group B. Nat Genet. 2004;36(11):1219–1224.15502827
   PubMed Web of Science ®Google Scholar
• Ceccaldi R, Sarangi P, D’Andrea AD. The Fanconi anaemia pathway: new players and new functions. Nat Rev Mol Cell Biol. 2016;17(6):337–349.27145721
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Nandi S. DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway. Cell Commun Signal. 2017;15(1):41.29017571
   PubMed Web of Science ®Google Scholar
• Cheung RS, Taniguchi T. Recent insights into the molecular basis of Fanconi anemia: genes, modifiers, and drivers. Int J Hematol. 2017;106(3):335–344.28631178
   PubMed Web of Science ®Google Scholar
• Sims AE, Spiteri E, Sims RJ 3rd, et al. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol. 2007;14(6):564–567.17460694
   PubMed Web of Science ®Google Scholar
• Smogorzewska A, Matsuoka S, Vinciguerra P, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell. 2007;129(2):289–301.17412408
   PubMed Web of Science ®Google Scholar
• D’Andrea AD. Susceptibility pathways in Fanconi’s anemia and breast cancer. N Engl J Med. 2010;362(20):1909–1919.20484397
   PubMed Web of Science ®Google Scholar
• Medhurst AL, El Laghmani H, Steltenpool Jet al. Evidence for subcomplexes in the Fanconi anemia pathway. Blood. 2006;108(6):2072–2080.16720839
   PubMed Web of Science ®Google Scholar
• Sumpter R Jr., Levine B. Emerging functions of the Fanconi anemia pathway at a glance. J Cell Sci. 2017;130(16):2657–2662.28811338
   PubMed Web of Science ®Google Scholar
• Scheckenbach K, Wagenmann M, Freund M, Schipper J, Hanenberg H. Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines. Klin Padiatr. 2012;224(3):132–138.22504776
   PubMed Web of Science ®Google Scholar
• Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg. 2003;129(1):106–112.12525204
   PubMed Web of Science ®Google Scholar
• Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica. 2018;103(1):30–39.29051281
   PubMed Web of Science ®Google Scholar
• Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica. 2008;93(4):511–517.18322251
   PubMed Web of Science ®Google Scholar
• Alter BP. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 2014;27(3–4):214–221.25455269
   PubMed Web of Science ®Google Scholar
• Salum FG, Martins GB, de Figueiredo MA, Cherubini K, Yurgel LS, Torres-Pereira C. Squamous cell carcinoma of the tongue after bone marrow transplantation in a patient with Fanconi anemia. Braz Dent J. 2006;17(2):161–165.16924346
   PubMedGoogle Scholar
• Guardiola P, Socié G, Li X, et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood. 2004;103(1):73–77.12946993
   PubMed Web of Science ®Google Scholar
• Spanier G, Pohl F, Giese T, Meier JK, Koelbl O, Reichert TE. Fatal course of tonsillar squamous cell carcinoma associated with Fanconi anaemia: a mini review. J Cranio-Maxillo Facial Surg. 2012;40(6):510–515.
   PubMed Web of Science ®Google Scholar
• Francies FZ, Wainwright R, Poole J, et al. Diagnosis of Fanconi Anaemia by ionising radiation- or mitomycin C-induced micronuclei. DNA Repair (Amst). 2018;61:17–24.29154021
   PubMed Web of Science ®Google Scholar
• Rosenberg PS, Tamary H, Alter BP. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. Am J Med Genet A. 2011;155a(8):1877–1883.21739583
   PubMed Web of Science ®Google Scholar
• Kutler DI, Auerbach AD. Fanconi anemia in Ashkenazi Jews. Fam Cancer. 2004;3(3–4):241–248.15516848
   PubMedGoogle Scholar
• Callén E, Casado JA, Tischkowitz MD, et al. A common founder mutation in FANCA underlies the world’s highest prevalence of Fanconi anemia in Gypsy families from Spain. Blood. 2005;105(5):1946–1949.15522956
   PubMed Web of Science ®Google Scholar
• Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101(3):822–826.12393424
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S, Calzone R, Grimaldi F, Zatterale A. Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned. Haematologica. 2016;101(3):319–327.26635036
   PubMed Web of Science ®Google Scholar
• Alter BP, Greene MH, Velazquez I, Rosenberg PS. Cancer in Fanconi anemia. Blood. 2003;101(5):2072.12584146
   PubMed Web of Science ®Google Scholar
• Asur RS, Kimble DC, Lach FP, et al. Somatic mosaicism of an intragenic FANCB duplication in both fibroblast and peripheral blood cells observed in a Fanconi anemia patient leads to milder phenotype. Mol Genetics Genomic Med. 2018;6(1):77–91.29193904
   PubMed Web of Science ®Google Scholar
• Fiesco-Roa MO, Giri N, McReynolds LJ, Best AF, Alter BP. Genotype-phenotype associations in Fanconi anemia: a literature review. Blood Rev. 2019;37:100589.31351673
   PubMed Web of Science ®Google Scholar
• Best DL, Spresser W, Shivers P, Edwards SP, Ward BB. Squamous cell carcinoma of the tongue in young patients: a case series and literature review. J Oral Maxillofacial Surg. 2020.
   Google Scholar
• Nolan M, Courtney R, Sexton P, Barry T, McCann PJ. Aggressive recurrence of oral squamous cell carcinoma in a patient with Fanconi’s Anaemia (FA). Ir Med J. 2017;110(3):533.28657246
   PubMedGoogle Scholar
• Chao JW, Cohen BD, Rohde CH, Kutler DI, Spector JA. Free fibular flap reconstruction of the mandible in a patient with Fanconi anemia. Plast Reconstr Surg. 2010;125(2):61e–63e.
   PubMed Web of Science ®Google Scholar
• Kaplan KA, Reiffel AJ, Kutler DI, Rohde CH, Spector JA. Sequential second free flap for head and neck reconstruction in a patient with fanconi anemia and metachronous squamous cell carcinoma. Plast Reconstr Surg. 2011;128(1):18e–19e.
   PubMed Web of Science ®Google Scholar
• Kutler DI, Patel KR, Auerbach AD, et al. Natural history and management of Fanconi anemia patients with head and neck cancer: a 10-year follow-up. The Laryngoscope. 2016;126(4):870–879.26484938
   PubMed Web of Science ®Google Scholar
• Wong WM, Parvathaneni U, Jewell PD, et al. Squamous cell carcinoma of the oral tongue in a patient with Fanconi anemia treated with radiotherapy and concurrent cetuximab: a case report and review of the literature. Head Neck. 2013;35(10):E292–298.22965917
   PubMed Web of Science ®Google Scholar
• Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386–396.26944243
   PubMed Web of Science ®Google Scholar
• Birkeland AC, Auerbach AD, Sanborn E, et al. Postoperative clinical radiosensitivity in patients with fanconi anemia and head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2011;137(9):930–934.21930984
   PubMedGoogle Scholar
• Alter BP. Radiosensitivity in Fanconi’s anemia patients. Radiother Oncol. 2002;62(3):345–347.12175566
   PubMed Web of Science ®Google Scholar
• Bremer M, Schindler D, Gross M, Dork T, Morlot S, Karstens JH. Fanconi’s anemia and clinical radiosensitivity report on two adult patients with locally advanced solid tumors treated by radiotherapy. Strahlenther Onkol. 2003;179(11):748–753.14605744
   PubMed Web of Science ®Google Scholar
• Budrukkar A, Shahid T, Murthy V, et al. Squamous cell carcinoma of base of tongue in a patient with Fanconi’s anemia treated with radiation therapy: case report and review of literature. Head Neck. 2010;32(10):1422–1427.19672872
   PubMed Web of Science ®Google Scholar
• Bernard ME, Kim H, Berhane H, et al. GS-nitroxide (JP4-039)-mediated radioprotection of human Fanconi anemia cell lines. Radiat Res. 2011;176(5):603–612.21939290
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127.18784101
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–578.16467544
   PubMed Web of Science ®Google Scholar
• Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J clin oncol. 2013;31(11):1405–1414.23460714
   PubMed Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J clin oncol. 2009;27(11):1864–1871.19289630
   PubMed Web of Science ®Google Scholar
• Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised Phase 3 trial. Lancet Oncol. 2015;16(5):583–594.25892145
   PubMed Web of Science ®Google Scholar
• Jung HS, Byun GW, Lee KE, et al. Gefitinib trial in a fanconi’s anemia patient with multiple squamous cell carcinomas and hepatocellular carcinoma. Cancer Res Treatment. 2005;37(6):370–373.
   Google Scholar
• Montanuy H, Martínez-Barriocanal Á, Antonio casado J, et al. Gefitinib and afatinib show potential efficacy for fanconi anemia-related head and neck cancer. Clin Cancer Res. 2020;26(12):3044–3057.32005748
   PubMed Web of Science ®Google Scholar
• Ayas M, Siddiqui K, Al-Jefri A, et al. Successful outcome in patients with Fanconi Anemia undergoing T cell-replete mismatched related donor hematopoietic cell transplantation using reduced-dose cyclophosphamide post-transplantation. Biol Blood Marrow Transplant. 2019;25(11):2217–2221.31306778
   PubMed Web of Science ®Google Scholar
• Ferris RL, Haddad R, Even C, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31(7):942–950.32294530
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965.27247226
   PubMed Web of Science ®Google Scholar